伏利诺斯塔特的临床有效性背后的抗癌机制的随机性
Nasreddine El Omari1, Asaad Khalid2,3, Hafiz A Makeen4
1High Institute of Nursing Professions and Health Techniques of Tetouan, Tetouan, Morocco.
Heliyon
|July 18, 2024
概括
伏利诺斯塔特是一种基因脱乙酶抑制剂 (HDACi),通过恢复基因表达和促进亡来对抗癌症. 这项研究调查了其精确的分子机制,以改善癌症治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 沃里诺斯塔特 (Zolinza®) 是FDA批准的用于癌症治疗的基因组脱乙酶抑制剂 (HDACi).
- HDAC通过增加基因组乙化来起作用,这可以恢复正常的基因表达,并激活癌细胞中的信号通路.
- 沃里诺斯塔特已经在各种癌症细胞系中证明了基因组乙化,细胞毒性,细胞循环蛋白调节,以及改变了亡因子水平.
研究的目的:
- 阐明伏利诺斯塔特抑制组织脱乙酶 (HDACs) 的精确分子机制.
- 为了加深对癌细胞异常的理解.
- 确定癌症治疗的新疗法策略.
主要方法:
- 这项研究的重点是阐明vorinostat的HDAC抑制的分子机制.
- 实验验证了沃里诺斯塔特对胰岛素乙化和细胞毒性的作用.
- 分析伏利诺斯塔特对特定分子点和途径的影响.
主要成果:
- 伏利诺斯塔特在许多癌症细胞系中诱导了基因素乙化和细胞毒性.
- 它增加了p21细胞周期蛋白质,增强了亲亡的因素,同时减少了抗亡的因素.
- 伏利诺斯塔特上调调节被编程的死亡配体1 (PD-L1) 和干扰素玛受体1 (IFN-γR1) 的表达,影响免疫反应.
结论:
- 沃里诺斯塔特的HDAC抑制作用对癌细胞生物学有广泛的影响,包括基因表达,亡和免疫调节.
- 了解这些机制对于优化伏利诺斯塔特治疗和开发新型癌症治疗至关重要.
- 对沃里诺斯塔特分子点的进一步研究可能会开辟新的治疗途径.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K